Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray

Technology in Cancer Research and Treatment

Volumn 5, Issue 6, 2006, Pages 543-551

  Akkiprik, Mustafa ^a,b   Nicorici, Daniel ^a,c   Cogdell, David ^a   Jia, Yu Jack ^a   Hategan, Andrea ^c   Tabus, Ioan ^c   Yli Harja, Olli ^c   Yu, Dihua ^a   Sahin, Aysegul ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

and EGFR; Breast cancer; ER; p53; Pathway; Protein lysate array

Indexed keywords

ANGIOPOIETIN RECEPTOR; APOPTOSIS INDUCING FACTOR; CASPASE 9; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEXOKINASE ISOENZYME 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; PROTEIN ND2; PROTEIN P19; PROTEIN P53; PROTEIN TYROSINE KINASE; SERINE; SOMATOMEDIN BINDING PROTEIN 5; STEM CELL FACTOR; THREONINE; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVERSE PHASE PROTEIN LYSATE MICROARRAY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 33846183301     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460600500601     Document Type: Article

References (41)

1. Templin, M. F., Stoll, D., Schwenk, J. M., Potz, O., Kramer, S., and Joos, T. O. Protein Microarrays: Promising Tools for Proteomic Research. Proteomics 3, 2155-2166 (2003).
2. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin, E. F., III, and Liotta, L. A. Reverse Phase Protein Microarrays Which Capture Disease Progression Show Activation of Pro-survival Pathways at the Cancer Invasion Front. Oncogene 20, 1981-1989 (2001).
3. Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., et al. Proteomic Profiling of the NCI-60 Cancer Cell Lines Using New High-density Reverse-phase Lysate Microarrays. Proc Natl Acad Sci USA 100, 14229-14234 (2003).
4. Jiang, R., Mircean, C., Shmulevich, I., Cogdell, D., Jia, Y., Tabus, I., Aldape, K., Sawaya, R., Bruner, J. M., Fuller, G. N., et al. Pathway Alterations During Glioma Progression Revealed by Reverse Phase Protein Lysate Arrays. Proteomics 6, 2964-2971 (2006).
5. Tabus, I., Hategan, A., Mircean, C., Rissanen, J., Shmulevich, I., Zhang, W., and Astola, J. Nonlinear Modeling of Protein Expressions in Protein Arrays. IEEE Transactions on Signal Processing 54, 2394-2407 (2006).
6. Bolstad, B. M., Irizarry, R. A., Astrand, M., and Speed, T. P. A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Variance and Bias. Bioinformatics 19, 185-193 (2003).
7. Dudoit, S., Fridlyand, J., and Speed, T. P. Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data. Journal of the American Statistical Association 97, 77-87 (2002).
8. Benjamini, Y. and Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289-300 (1995).
9. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., and Golani, I. Controlling the False Discovery Rate in Behavior Genetics Research. Behav Brain Res 125, 279-284 (2001).
10. Storey, J. D. and Tibshirani, R. Statistical Significance for Genomewide Studies. Proc Natl Acad Sci USA 100, 9440-9445 (2003).
11. Van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer, Nature 415, 530-536 (2002).
12. Hao, X., Sun, B., Hu, L., Lahdesmaki, H., Dunmire, V., Feng, Y., Zhang, S. W., Wang, H., Wu, C., Wang, H., et al. Differential Gene and Protein Expression in Primary Breast Malignancies and Their Lymph Node Metastases as Revealed by Combined cDNA Microarray and Tissue Microarray Analysis. Cancer 100, 1110-1122 (2004).
13. Russo, V. C., Schutt, B. S., Andaloro, E., Ymer, S. I., Hoeflich, A., Ranke, M. B., Bach, L. A., and Werther, G. A. Insulin-like Growth Factor Binding Protein-2 Binding to Extracellular Matrix Plays a Critical Role in Neuroblastoma Cell Proliferation, Migration, and Invasion. Endocrinology 146, 4445-4455 (2005).
14. Lee, E. J., Mircean, C., Shmulevich, I., Wang, H., Liu, J., Niemisto, A., Kayanagh, J. J., Lee, J. H., and Zhang, W. Insulin-like Growth Factor Binding Protein 2 Promotes Ovarian Cancer Cell Invasion. Mol Cancer 4, 7 (2005).
15. Wang, H., Wang, H., Shen, W., Huang, H., Hu, L., Ramdas, L., Zhou, Y. H., Liao, W. S., Fuller, G. N., and Zhang, W. Insulin-like Growth Factor Binding Protein 2 Enhances Glioblastoma Invasion by Activating Invasion-enhancing Genes. Cancer Res 63, 4315-4321 (2003).
16. Osborne, C. K. Tamoxifen in the Treatment of Breast Cancer. N Engl J Med 339, 1609-1618 (1998).
17. Petricoin, E. F. 3rd, Bichsel, V. E., Calvert, V. S., Espina, V., Winters, M., Young, L., Belluco, C., Trock, B. J., Lippman, M., Fishman, D. A., et al. Mapping Molecular Networks Using Proteomics: A Vision for Patient-tailored Combination Therapy. J Clin Oncol 23, 3614-3621 (2005).
18. Wulfkuhle, J. D., Edmiston, K. H., Liotta, L. A., Petricoin, E. F. Technology Insight: Pharmacoproteomics for Cancer-promises of Patient-tailored Medicine Using Protein Microarrays. Nat Clin Pract Oncol 3, 256-68 (2006).
19. Gulmann, C., Sheehan, K., Kay, E., Liotta, L., Petricoin, E., 3rd. Array-based Proteomics: Mapping of Protein Circuitries for Diagnostics, Prognostics, and Therapy Guidance in Cancer. J Pathol 208, 595-606 (2006).
20. Gulmann, C., Espina, V., Petricoin, E., Longo, D. L., Santi, M., Knutsen, T., Raffeld, M., Jaffe, E. S., Liotta, L. A., Feldman, A. L. Proteomic Analysis of Apoptotic Pathways Reveal Prognostic Factors in Follicular Lymphoma. Clin Cancer Res 11, 5847-55 (2005).
21. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K., and Clark, G. M. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. J Clin Oncol 21, 1973-1979 (2003).
22. Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Arpino, G., Rimawi, M., and Osborne, C. K. Advanced Concepts in Estrogen Receptor Biology and Breast Cancer Endocrine Resistance: Implicated Role of Growth Factor Signaling and Estrogen Receptor Coregulators. Cancer Chemother Pharmacol Suppl 1, 10-20 (2005).
23. Osborne, C. K., Shou, J., Massarweh, S., and Schiff, R. Crosstalk Between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer. Clin Cancer Res 11, 865s-870s (2005).
24. Lin, H. J., Hsieh, F. C., Song, H., and Lin, J. Elevated Phosphorylation and Activation of PDK-1/AKT in Human Breast Cancer. Br J Cancer 93, 1372-1381 (2005).
25. Tokunaga, E., Kataoka, A., Kimura, Y., Oki, E., Mashino, K., Nishida, K., Koga, T., Morita, M., Kakeji, Y., Baba, H., et al. The Association Between Akt Activation and Resistance to Hormone Therapy in Metastatic Breast Cancer. Eur J Cancer 42, 629-635 (2006).
26. Tokunaga, E., Kimura, Y., Oki, E., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., Baba, H., et al. Akt is Frequently Activated in HER2/neu-positive Breast Cancer and Associated with Poor Prognosis Among Hormone-treated Patients. Int J Cancer 118, 284-289 (2006).
27. Clemmons, D. R., Camacho-Hubner, C., Coronado, E., and Osborne, C. K. Insulin-like Growth Factor Binding Protein Secretion by Breast Carcinoma Cell Lines: Correlation with Estrogen Receptor Status. Endocrinology 127, 2679-2686 (1990).
28. Yee, D., Sharma, J., and Hilsenbeck, S. G. Prognostic Significance of Insulin-like Growth Factor-binding Protein Expression in Axillary Lymph Node-negative Breast Cancer. J Natl Cancer Inst 86, 1785-1789 (1994).
29. Sheikh, M. S., Shao, Z. M., Clemmons, D. R., LeRoith, D., Roberts, C. T., Jr., and Fontana, J. A. Identification of the Insulin-like Growth Factor Binding Proteins 5 and 6 (IGFBP-5 and 6) in Human Breast Cancer Cells. Biochem Biophys Res Commun 183, 1003-1010 (1992).
30. Allander, S. V., Larsson, C., Ehrenborg, E., Suwanichkul, A., Weber, G., Morris, S. L., Bajalica, S., Kiefer, M. C., Luthman, H., and Powell, D. R. Characterization of the Chromosomal Gene and Promoter for Human Insulin-like Growth Factor Binding Protein-5. J Biol Chem 269, 10891-10898 (1994).
31. Butt, A. J., Dickson, K. A., McDougall, F., and Baxter, R. C. Insulin-like Growth Factor-binding Protein-5 Inhibits the Growth of Human Breast Cancer Cells In Vitro and In Vivo. J Biol Chem 278, 29676-29685 (2003).
32. Perks, C. M., Bowen, S., Gill, Z. P., Newcomb, P. V., and Holly, J. M. Differential IGF-independent Effects of Insulin-like Growth Factor Binding Proteins (1-6) on Apoptosis of Breast Epithelial Cells. J Cell Biochem 75, 652-664 (1999).
33. Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., and Lee, A. V. Insulin-like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-kinase/Akt/Mammalian Target of Rapamycin Pathway. Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer. Mol Endocrinol 17, 575-588 (2003).
34. Hennipman, A., van Oirschot, B. A., Smits, J., Rijksen, G., and Staal, G. E. J. Tyrosine Kinase Activity in Breast Cancer, Benign Breast Disease, and Normal Breast Tissue. Cancer Res 49, 516-521 (1989).
35. Verbeek, B. S., Vroom, T. M., Adriansen-Slot, S. S., Otthenoff-Kalff, A. E., Geertzema, J. G., Hennipman, A., and Rijksen, G. c-Src Protein Expression is Increased in Human Breast Cancer. An Immunohistochemical and Biochemical Analysis. J Pathol 180, 383-388 (1996).
36. Myoui, A., Nishimura, A., Williams, P. J., Tamura, D., Michigami, T., Mundy, G. R., and Yoneda, T. c-Src Tyrosine Kinase Activity is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis. Cancer Res 63, 5028-5033 (2003).
37. Rucci, N., Recchia, I., Angelucci, A., Alamanou, M., Del Fattore, A., Fortunati, D., Susa, M., Fabbro, D., Bologna, M., and Teti, A. Inhibition of Protein Kinase c-src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice. Implications for Therapy. J Pharmacol Exp Ther, in press (2006).
38. Tanno, S., Tanno, S., Mitsuuchi, Y., Altomare, D. A., Xiao, G. H., and Testa, J. R. AKT Activation Up-regulates Insulin-like Growth Factor I Receptor Expression and Promotes Invasiveness of Human Pancreatic Cancer Cells. Cancer Res 61, 589-593 (2001).
39. Ballare, C., Uhrig, M., Bechtold, T., Sancho, E., Di Domenico, M., Migliaccio, A., Auricchio, F., and Beato, M. Two Domains of the Progesterone Receptor Interact with the Estrogen Receptor and are Required for Progesterone Activation of the c-Src/Erk Pathway in Mammalian Cells. Mol Cell Biol 23, 1994-2008 (2003).
40. Boonyaratanakornkit, V., Scott, M. P., Ribon, V., Sherman, L., Anderson, S. M., Maller, J. L., Miller, W. T., and Edwards, D. P. Progesterone Receptor Contains a Proline-rich Motif that Directly Interacts with SH3 Domains and Activates c-Src Family Tyrosine Kinases. Mol Cell 8, 269-280 (2001).
41. Stambolsky, P., Weisz, L., Shats, L., Klein, Y., Goldfinger, N., Oren, M., and Rotter, V. Regulation of AIF Expression by p53. Cell Death Differ, in press (2006).